Content about Novartis

August 20, 2013

Generic drug maker Sandoz has relaunched a website to promote its biosimilars business.

NEW YORK — Generic drug maker Sandoz has relaunched a website to promote its biosimilars business.

August 19, 2013

The Exchange, Safeway and Walmart were among the companies identified as the nation's top veteran-friendly companies by the U.S. Veterans Magazine last week.

IRVINE, Calif. — The Exchange, Safeway and Walmart were among the companies identified as the nation's top veteran-friendly companies by the U.S. Veterans Magazine last week. The publication released the results of its 2013 evaluation of the nation's top veteran-friendly companies, which also included 3M, the Coca-Cola Company, Kellogg Co., Novartis, Sears Holdings and Target, following a poll of Fortune 1000 companies.  

August 8, 2013

Both Novartis Consumer Health and McNeil Consumer Healthcare will be making strong comebacks across their respective analgesic portfolios in the second half of this year, which will make a fourth-quarter battle royale across analgesics, as well as cough-cold.

Both Novartis Consumer Health and McNeil Consumer Healthcare will be making strong comebacks across their respective analgesic portfolios in the second half of this year, which will make a fourth-quarter battle royale across analgesics, as well as cough-cold.

August 2, 2013

The Food and Drug Administration has approved a vaccine against meningococcal disease for use among patients of a broader age range than before.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved a vaccine against meningococcal disease for use among patients of a broader age range than before.

July 26, 2013

A federal court has ruled in favor of generic drug maker Sandoz in a case involving a drug for multiple sclerosis, Sandoz said.

PRINCETON, N.J. — A federal court has ruled in favor of generic drug maker Sandoz in a case involving a drug for multiple sclerosis, Sandoz said.

Sandoz, the generics division of Switerland-based Novartis, said the U.S. Federal Circuit Court of Appeals invalidated nine patents owned by Israel-based Teva Pharmaceutical Industries covering the drug Copaxone (glatiramer acetate).

July 22, 2013

The Food and Drug Administration has approved a drug made by Japanese drug maker Astellas for preventing the body from rejecting transplanted organs, the company said.

NORTHBROOK, Ill. — The Food and Drug Administration has approved a drug made by Japanese drug maker Astellas for preventing the body from rejecting transplanted organs, the company said.

Astellas announced through a U.S. subsidiary that the FDA had approved Astagraf XLTM (tacrolimus) extended-release capsules for preventing rejection of transplanted kidneys, for use with Genentech's CellCept (mycophenolate mofetil) and corticosteroids, with or without Simulect (basiliximab), a biotech drug made by Swiss drug maker Novartis.

July 22, 2013

An announcement Monday by generic drug maker Sandoz gives a glimpse of what could happen in the United States when biosimilars start to become available.

HOLZKIRCHEN, Germany — An announcement Monday by generic drug maker Sandoz gives a glimpse of what could happen in the United States when biosimilars start to become available.

July 17, 2013

Johnson & Johnson will be making a strong comeback across its portfolio of McNeil Consumer Healthcare recalled OTC products in the fourth quarter of this year.

NEW BRUNSWICK, N.J. — Johnson & Johnson will be making a strong comeback across its portfolio of McNeil Consumer Healthcare recalled OTC products in the fourth quarter of this year. And with a J&J pledge to partner with key retail partners "on strategic relationships that are rebuilding our relationships and supporting their health and wellness strategies," this fourth quarter will likely be more promotional all around. 

July 2, 2013

Sandoz, the generics division of Swiss drug maker Novartis, announced the launch of metronidazole 1% topical gel, calling it the first generic version of Galderma Labs' Metrogel.

PRINCETON, N.J. — Sandoz has launched a generic topical drug for rosacea, the drug maker said Tuesday.

Sandoz, the generics division of Swiss drug maker Novartis, announced the launch of metronidazole 1% topical gel, calling it the first generic version of Galderma Labs' Metrogel. The drug is indicated for treating inflammatory lesions of rosacea, estimated to affect about 16 million Americans.

Metrogel had sales of about $110 million during the 12-month period that ended in April, according to IMS Health.

July 2, 2013

Sandoz has started a late-stage clinical trial of a biosimilar version of a drug used to treat autoimmune disorders, hoping the results will support its efforts to win regulatory approval in the United States and Europe.

HOLZKIRCHEN, Germany — Sandoz has started a late-stage clinical trial of a biosimilar version of a drug used to treat autoimmune disorders, hoping the results will support its efforts to win regulatory approval in the United States and Europe.

Sandoz, the generics arm of Swiss drug maker Novartis, said it had started a phase-3 trial of biosimilar etanercept, a knock-off version of Amgen's Enbrel, used to treat chronic plaque-type psoriasis.

May 22, 2013

The Food and Drug Administration has approved a generic heart disease drug made by Sandoz, the company said.

PRINCETON, N.J. — The Food and Drug Administration has approved a generic heart-disease drug made by Sandoz, the company said Wednesday.

Sandoz, the generics division of Swiss drug maker Novartis, announced the approval of candesartan cilexetil tablets, a generic version of AstraZeneca's Atacand.

The drug is used to treat some types of heart failure in adults with left ventricular systolic dysfunction, as well as high blood pressure in adults and children as young as 1.

Atacand had sales of $120.3 million in 2012, according to IMS Health.

May 22, 2013

Generic drug maker Par Pharmaceutical Cos. has started shipping an authorized generic version of a heart-disease medication made by AstraZeneca.

WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical Cos. has started shipping an authorized generic version of a heart-disease medication made by AstraZeneca.

Par said it had entered into an agreement with AstraZeneca to supply authorized generic Atacand (candesartan cilexetil) and had begun shipping the drug in the 4 mg, 8 mg, 16 mg and 32 mg strengths. Atacand has annual sales of about $113 million, according to IMS Health, and is used to treat certain kinds of heart failure and high blood pressure in children and adults.

May 10, 2013

The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday.

April 24, 2013

A dramatic jump in the rates of misuse of prescription stimulants over the past four years is linked to lax attitudes on the part of parents, according to a new study, though misuse and abuse of prescription opioids has remained flat.

NEW YORK — A dramatic jump in the rates of misuse of prescription stimulants over the past four years is linked to lax attitudes on the part of parents, according to a new study, though misuse and abuse of prescription opioids has remained flat.

April 23, 2013

Sandoz U.S. Generics Operating Unit VP sales and marketing Rich Tremonte will leave the company.

PRINCETON, N.J. — Sandoz U.S. Generics Operating Unit VP sales and marketing Rich Tremonte will leave the company.

The company said Tremonte would be working for AmerisourceBergen Corp. as VP global generic pharmaceuticals starting on June 1.

 

April 22, 2013

The Food and Drug Administration has approved a drug made by Alcon, the drug maker said.

BASEL, Switzerland — The Food and Drug Administration has approved a drug made by Alcon, the drug maker said.

April 17, 2013

Generic drug maker Sandoz has launched a generic version of a drug used to treat high blood pressure and angina.

PRINCETON, N.J. — Generic drug maker Sandoz has launched a generic version of a drug used to treat high blood pressure and angina.

The company, a subsidiary of Swiss drug maker Novartis, announced the launch of diltiazem hydrochloride extended-release capsules, a generic version of Forest Labs' Tiazac. Sandoz is launching the drug in the 120-mg, 180-mg, 240-mg, 300-mg, 360-mg and 420-mg strengths.

Various versions of the drug had sales of about $174 million in 2012, according to IMS Health.

 

April 4, 2013

Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

HYDERABAD, India — Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis' Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.

April 4, 2013

Novartis is promoting the multiple sclerosis drug Gilenya to young people with a new ad campaign in several national magazine's and websites, according to published reports.

NEW YORK — Novartis is promoting the multiple sclerosis drug Gilenya to young people with a new ad campaign in several national magazine's and websites, according to published reports.

The New York Times reported that the Swiss drug maker had placed ads for its "Hey MS, Take This!" campaign in People, Shape and Self, as well as the website of women's magazines, in addition to online videos. The generic name of Gilenya is fingolimod.

April 2, 2013

A ruling by India's high court means cheaper generic versions of a cancer drug will remain available in developing countries, according to published reports.

NEW YORK — A ruling by India's high court means cheaper generic versions of a cancer drug will remain available in developing countries, according to published reports.

The New York Times reported that the Indian Supreme Court ruled drug companies there could keep making generic versions of Swiss drug maker Novartis' leukemia medication Gleevec (imatinib). According to the Times, generic versions of Gleevec in India cost about $2,500 per year, compared with $70,000 per year for the branded version.

March 25, 2013

The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

Swiss drug maker Novartis announced the approval of Tobi Podhaler (tobramycin inhalation powder) for managing cystic fibrosis patients with Pseudomonas aeruginosa, or Pa bacteria, in the lungs.

March 20, 2013

The Food and Drug Administration has approved and launched two generic contraceptives made by Sandoz, the drug maker said.

PRINCETON, N.J. — The Food and Drug Administration has approved and launched two generic contraceptives made by Sandoz, the drug maker said.

Sandoz, the generics division of Swiss drug maker Novartis, announced the approval of Estarylla (norgestimate and ethinyl estradiol tablets) and Tri-Estarylla (norgestimate and ethinyl estradiol tablets), generic versions of Johnson & Johnson's Ortho Cyclen and Ortho Tri-Cyclen, respectively. Sandoz said the launches brought the total number of oral contraceptives it has launched since the beginning of 2011 to six.

March 12, 2013

Actavis is challenging Novartis' patent on a patch used to treat Alzheimer's disease, Actavis said.

PARSIPPANY, N.J. — Actavis is challenging Novartis' patent on a patch used to treat Alzheimer's disease, Actavis said.

The generic drug maker said it had filed with the Food and Drug Administration an amendment to its regulatory application for rivastigmine transdermal system to include the 13.3 mg-per-24-hours dosage strength, a generic version of Novartis' Exelon. Novartis filed suit against Actavis on Thursday in the U.S. District Court for the District of Delaware seeking to prevent commercialization of the generic version.

March 8, 2013

With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls.

With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls. Within internal analgesic tablets, sales of store brand equivalents were up 15% off of a 2011 base of around $1.2 billion. The branded competition also were benefactors — both Pfizer's Advil and Bayer's Aleve generated more than $50 million in incremental sales on top of 2011 sales.

March 5, 2013

Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

Dr. Reddy's announced the launch of injectable zoledronic acid in the 4-mg-per-5-mL strength. The launch followed the Food and Drug Administration's approval of the drug.

The drug is a generic version of Novartis' Zometa. The drug is used to treat cancers that have spread to the bones and multiple myeloma.

CORRECTION: An earlier version of this story misstated the strength of the drug. The story has been corrected.